Your browser version may not work well with NCBI's Web applications. More information here...
1: Otolaryngol Head Neck Surg. 2007 Dec;137(6):918-24.Click here to read Links
Erratum in:
Otolaryngol Head Neck Surg. 2008 Feb;138(2):258. Beezley, Susan F [corrected to Beezley, Sally F].

An assessment of the onset and duration of action of olopatadine nasal spray.

Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, Beezley SF, Drake M, Potts SL, Wall GM.

Allied Research International, Mississauga, ON, Canada. ppatel@allied-research.com

OBJECTIVE: Seasonal allergic rhinitis (SAR) is a highly prevalent disease. This study was conducted to evaluate the onset and duration of action of three concentrations of olopatadine nasal spray. METHODS: This was a randomized, double-blind, single-dose, placebo-controlled study, conducted in an environmental exposure chamber in patients with SAR. A total of 320 patients were exposed to ragweed allergen in the chamber and randomized to olopatadine nasal spray 0.2%, 0.4%, 0.6%, or placebo nasal spray. Symptoms (sneezing, runny, itchy, and stuffy nose) were self-assessed during a 12-hour study period. RESULTS: All concentrations of olopatadine nasal spray provided clinically meaningful reductions in total nasal symptom scores at 30 minutes compared to the placebo. Olopatadine nasal spray 0.6% was significantly more effective (P < 0.05) than placebo nasal spray at all time-points starting at 90 minutes post-dose and continuing over 12 hours. CONCLUSIONS: Olopatadine nasal spray 0.6% demonstrated a fast onset of action and maintained an effect for at least 12 hours after dosing.

PMID: 18036421 [PubMed - indexed for MEDLINE]